top of page
Search

Boston Scientific Invests $1.5bn for Strategic Equity Stake in MiRus TAVR Platform

  • Writer: nuaxia
    nuaxia
  • 6 days ago
  • 3 min read

Strengthening its structural heart pipeline, Boston Scientific expands into next-generation transcatheter aortic valve technology with an optional full acquisition pathway.


Boston Scientific has agreed to invest $1.5bn to acquire a 34% equity stake in MiRus, gaining exposure to its SIEGEL Balloon Expandable transcatheter aortic valve replacement (TAVR) system, with an option to acquire full ownership of the TAVR business for up to an additional $3bn contingent on clinical and regulatory milestones.

The deal reinforces Boston Scientific’s strategy of expanding its structural heart franchise through differentiated valve technologies, while securing an option-driven pathway to fully integrate a next-generation TAVR platform into its cardiovascular portfolio.

A Strategic Entry Into Next-Generation TAVR Technology

At the centre of the transaction is MiRus’ SIEGEL TAVR system, a balloon-expandable valve featuring a rhenium alloy frame designed to eliminate nickel exposure and improve biocompatibility in patients with severe aortic stenosis.

The valve uses dry porcine tissue leaflets combined with a nitric oxide-coated rhenium frame engineered for high radial strength, with an open-cell design intended to support precise placement and reduce foreshortening during deployment.

The system is delivered via an 8-Fr expandable sheath, approximately 50% smaller than many current commercial TAVR delivery systems, with the potential to reduce vascular complications and improve procedural access in higher-risk patient populations.

Expanding Clinical Development and Platform Optionality

MiRus has initiated the STAR pivotal trial evaluating the SIEGEL valve across multiple sizes in up to 1,025 patients with severe, symptomatic aortic stenosis across a range of surgical risk profiles.

Boston Scientific’s agreement includes milestone-based optionality to acquire full control of the TAVR business, as well as additional potential payments tied to regulatory progress and net sales performance, alongside an exclusive option to acquire MiRus mitral and tricuspid valve technologies.

This structure provides Boston Scientific with staged exposure to both clinical validation and commercial scalability before committing to full acquisition.

Why This Deal Matters Now

The investment reflects increasing competition in structural heart innovation, particularly in TAVR systems where device miniaturisation, deliverability, and long-term durability are becoming key differentiators.

As the prevalence of aortic stenosis continues to rise, device manufacturers are competing to expand procedural access through lower-profile delivery systems and improved haemodynamic performance, while also addressing biocompatibility concerns associated with existing materials.

MiRus’ rhenium-based architecture and reduced sheath size position the platform as a potential next-generation entrant in a mature but rapidly evolving TAVR market.


What This Means for the Industry

This transaction highlights three broader trends in medtech and structural heart investment:

  • Companies are increasingly using minority stakes to secure early access to differentiated platforms

  • Option-based acquisition structures are becoming a preferred de-risking mechanism in capital-intensive device development

  • Innovation focus is shifting toward access, deliverability, and material science in structural heart systems

At the same time, competition in TAVR remains intense, with established players continuing to iterate on device profiles, valve durability, and procedural outcomes.

Boston Scientific’s investment signals a continued push to build depth in structural heart therapies ahead of future market expansion and competitive consolidation.

Summary

Boston Scientific’s $1.5bn investment in MiRus strengthens its position in structural heart innovation while securing optional full ownership of a next-generation TAVR platform.

The deal reflects a broader industry shift toward staged acquisitions and differentiated device architectures aimed at improving procedural safety, access, and long-term patient outcomes in aortic stenosis.



Discover how nuaxia can support your next medical education initiative:

 
 
 

Comments

Rated 0 out of 5 stars.
No ratings yet
Add a rating
bottom of page